- Home
- APOG vs PRAX Comparison
APOG vs PRAX Comparison
Compare APOG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APOG
- PRAX
- Stock Information
- Founded
- APOG 1949
- PRAX 2015
- Country
- APOG United States
- PRAX United States
- Employees
- APOG N/A
- PRAX N/A
- Industry
- APOG Auto Parts:O.E.M.
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- APOG Consumer Discretionary
- PRAX Health Care
- Exchange
- APOG Nasdaq
- PRAX Nasdaq
- Market Cap
- APOG 818.5M
- PRAX 950.8M
- IPO Year
- APOG N/A
- PRAX 2020
- Fundamental
- Price
- APOG $42.41
- PRAX $56.92
- Analyst Decision
- APOG Hold
- PRAX Strong Buy
- Analyst Count
- APOG 1
- PRAX 10
- Target Price
- APOG $45.00
- PRAX $101.00
- AVG Volume (30 Days)
- APOG 355.7K
- PRAX 387.8K
- Earning Date
- APOG 06-27-2025
- PRAX 08-12-2025
- Dividend Yield
- APOG 2.45%
- PRAX N/A
- EPS Growth
- APOG N/A
- PRAX N/A
- EPS
- APOG 2.36
- PRAX N/A
- Revenue
- APOG $1,376,100,000.00
- PRAX $8,122,000.00
- Revenue This Year
- APOG $6.76
- PRAX N/A
- Revenue Next Year
- APOG N/A
- PRAX $4,434.72
- P/E Ratio
- APOG $17.96
- PRAX N/A
- Revenue Growth
- APOG N/A
- PRAX 270.02
- 52 Week Low
- APOG $37.53
- PRAX $26.70
- 52 Week High
- APOG $87.93
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- APOG 54.73
- PRAX 75.66
- Support Level
- APOG $42.34
- PRAX $53.89
- Resistance Level
- APOG $43.27
- PRAX $58.44
- Average True Range (ATR)
- APOG 1.03
- PRAX 3.03
- MACD
- APOG -0.07
- PRAX 0.50
- Stochastic Oscillator
- APOG 40.91
- PRAX 90.30
About APOG Apogee Enterprises Inc.
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.